- The 50IU, 100IU and 200IU formulations cover aesthetic and therapeutic indicatons
- The strong partnership with Medica Group will boost Hugel’s expansion in the MENA
The approval of Botulax in 50IU, 100IU, and 200IU covers five aesthetic and medical indications: eyelid spasm; crow’s feet; glabellar lines; upper extremity muscle spasticity after stroke; and cerebral palsy adduction deformity in children.
The company plans to officially release the toxin Botulax in the
Hugel will accelerate its market expansion with unique sales and marketing strategies in the region. Building on the success of its hyaluronic acid dermal filler Revolax, which won approval in the
The MENA represents one of the fastest-growing markets for medical aesthetics, driven by robust economic growth, favorable demographic trends, increasing social media engagement, and rising demand for aesthetic treatments. Hugel is preparing for the approval process of its toxin in other MENA countries such as
“We are excited about the growth potential in the MENA market with the approval for Botulax with aesthetic and therapeutic indications. Hugel will expand its business through the high quality of the toxin and Medica Group’s comprehensive understanding of the market and its active partnerships combined with the regional networks,” a Hugel official said.
About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in
Contact:
jihyun.kim@hugel-inc.com
